Atopic Clinical Trials

1 recruiting

Frequently Asked Questions

Common questions about Atopic clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 148 trials

Recruiting
Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Enveda Therapeutics64 enrolled17 locationsNCT07298395
Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 2

A Study Evaluating TRIV-509 in Atopic Dermatitis

Atopic Dermatitis
Triveni Bio90 enrolled44 locationsNCT07167758
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Atopic Dermatitis
Sanofi1,000 enrolled37 locationsNCT07290803
Recruiting
Phase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic Dermatitis
AbbVie200 enrolled121 locationsNCT06389136
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Dermatitis Atopic
Sanofi390 enrolled146 locationsNCT06241118
Recruiting
Phase 1

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Atopic Dermatitis
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.90 enrolled2 locationsNCT07488065
Recruiting
Phase 3

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
AbbVie675 enrolled148 locationsNCT06461897
Recruiting
Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Atopic Dermatitis
UCB Biopharma SRL160 enrolled23 locationsNCT07277660
Recruiting
Not Applicable

Dietary Intervention on Atopy

Atopic DermatitisAllergic DiseasesAllergic Rhinitis+1 more
National University of Singapore110 enrolled1 locationNCT06547372
Recruiting
Phase 2

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Novartis Pharmaceuticals84 enrolled27 locationsNCT07220577
Recruiting
Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled42 locationsNCT07003425
Recruiting

Collection of Samples From Subjects With Various Skin Conditions and Healthy Volunteers

Atopic DermatitisHidradenitis SuppurativaAcne+3 more
Innovaderm Research Inc.500 enrolled1 locationNCT05994976
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting
Phase 4

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Atopic Dermatitis
Eli Lilly and Company200 enrolled71 locationsNCT07006792
Recruiting
Phase 3

A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis

Atopic Dermatitis
LEO Pharma195 enrolled72 locationsNCT06311682
Recruiting
Phase 3

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Atopic Dermatitis
Pfizer500 enrolled26 locationsNCT06807281
Recruiting
Phase 1

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

Healthy ParticipantsAtopic Dermatitis
Pfizer119 enrolled2 locationsNCT06564389
Recruiting
Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche120 enrolled7 locationsNCT07223697